tiprankstipranks
Trending News
More News >
Hygeia Healthcare Holdings Co., Ltd. (HK:6078)
:6078
Hong Kong Market

Hygeia Healthcare Holdings Co., Ltd. (6078) AI Stock Analysis

Compare
1 Followers

Top Page

HK

Hygeia Healthcare Holdings Co., Ltd.

(6078)

Rating:66Neutral
Price Target:
Hygeia Healthcare's overall score reflects strong financial performance driven by revenue growth and profitability. However, concerns about cash flow generation and increasing debt levels slightly dampen the outlook. Technical indicators suggest neutral to bearish momentum, and while valuation appears reasonable, the lack of a dividend yield limits appeal for income-focused investors.

Hygeia Healthcare Holdings Co., Ltd. (6078) vs. iShares MSCI Hong Kong ETF (EWH)

Hygeia Healthcare Holdings Co., Ltd. Business Overview & Revenue Model

Company DescriptionHygeia Healthcare Holdings Co., Limited operates as an oncology healthcare company in the People's Republic of China. The company owns and operates private for-profit hospitals that offer oncology healthcare services, such as tumor screening and genetic diagnosis, radiotherapy, surgery, chemotherapy, immunotherapy, targeted therapy, oncology rehabilitation, nutrition, and hospice care. It also provides radiotherapy center consulting services; and licenses its SRT equipment, as well as offers maintenance and technical support services for its SRT equipment. In addition, the company provides hospital and corporate management, and supply chain services. As of December 31, 2021, it operated or managed a network of 12 oncology-focused hospitals in 9 cities in 7 Provinces in the People's Republic of China. Hygeia Healthcare Holdings Co., Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.
How the Company Makes MoneyHygeia Healthcare Holdings Co., Ltd. generates revenue primarily through the provision of healthcare services within its network of specialty hospitals and clinics. The key revenue streams include fees charged for diagnostic services, treatment procedures, and inpatient care. The company benefits from China's growing demand for oncology services, driven by an increasing incidence of cancer and a rising awareness of early diagnosis and treatment. Additionally, Hygeia Healthcare may engage in partnerships with medical technology providers to enhance its service offerings, although specific partnership details are null. The company's focus on cost-effective operations and expanding its hospital network further contributes to its revenue growth.

Hygeia Healthcare Holdings Co., Ltd. Financial Statement Overview

Summary
Hygeia Healthcare shows strong revenue growth and profitability, with a robust gross profit margin. However, challenges exist in cash flow generation, particularly in free cash flow and operating cash flow alignment. The balance sheet is stable with manageable leverage, but increasing debt levels could be a future concern.
Income Statement
85
Very Positive
Hygeia Healthcare demonstrated strong revenue growth and profitability. The gross profit margin was robust at 29.36% for 2024, showing effective cost management. However, net profit margin decreased slightly to 13.45%, indicating some pressure on bottom-line profitability. Revenue grew by 9.06% from 2023 to 2024, showcasing continued expansion, but the slower growth compared to previous years may warrant monitoring.
Balance Sheet
78
Positive
The company's balance sheet reflects a healthy equity position, with a debt-to-equity ratio of 0.42 in 2024, indicating manageable leverage. Return on equity was solid at 8.99%, though slightly down from the previous year, suggesting efficient use of equity capital. The equity ratio is healthy at 60.88%, highlighting financial stability. However, increasing total debt levels could pose future risks.
Cash Flow
60
Neutral
Cash flow analysis reveals challenges with free cash flow generation, as free cash flow was null in 2024. The operating cash flow to net income ratio is unavailable, suggesting a need for better alignment of operating cash flows to net income. The company must focus on enhancing cash flow from operations to support ongoing investments and debt obligations.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
4.45B4.08B3.20B2.32B1.40B
Gross Profit
1.31B1.29B1.02B744.66M471.96M
EBIT
821.14M889.10M735.77M525.61M318.13M
EBITDA
999.10M1.11B868.43M623.67M385.36M
Net Income Common Stockholders
598.26M682.93M476.78M441.46M170.09M
Balance SheetCash, Cash Equivalents and Short-Term Investments
651.59M768.00M884.71M1.10B2.58B
Total Assets
10.93B10.73B7.24B6.69B4.70B
Total Debt
2.79B2.72B1.29B1.23B2.48M
Net Debt
2.42B2.16B435.35M524.59M-382.62M
Total Liabilities
4.25B4.48B2.30B2.21B359.93M
Stockholders Equity
6.65B6.23B4.93B4.46B4.27B
Cash FlowFree Cash Flow
0.00-157.98M92.26M-236.84M-25.77M
Operating Cash Flow
0.00782.84M685.38M426.25M296.13M
Investing Cash Flow
0.00-2.86B-372.06M-850.85M-2.48B
Financing Cash Flow
0.001.78B-154.21M754.50M2.17B

Hygeia Healthcare Holdings Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price15.90
Price Trends
50DMA
14.60
Positive
100DMA
14.50
Positive
200DMA
16.05
Negative
Market Momentum
MACD
0.31
Negative
RSI
58.56
Neutral
STOCH
67.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6078, the sentiment is Positive. The current price of 15.9 is above the 20-day moving average (MA) of 15.23, above the 50-day MA of 14.60, and below the 200-day MA of 16.05, indicating a neutral trend. The MACD of 0.31 indicates Negative momentum. The RSI at 58.56 is Neutral, neither overbought nor oversold. The STOCH value of 67.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6078.

Hygeia Healthcare Holdings Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
HK$9.77B16.029.30%7.28%-13.77%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
$525.94M19.121.44%5.58%
$10.37B42.636.14%1.32%
$1.88B87.770.96%
$7.42B6.959.19%5.60%
DE2WI
€24.50M-151.78%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
16.52
-16.83
-50.46%
CYYHF
China Yongda Automobiles Services
0.28
0.07
33.33%
SBMFF
Sino Biopharmaceutical
0.63
0.29
85.29%
PANHF
Ping An Healthcare and Technology Company
0.90
0.74
462.50%
SHTDF
Sinopharm Group Co
2.18
-0.61
-21.86%
DE:2WI
Yunnan Water Investment Co., Limited Class H
0.02
0.00
0.00%

Hygeia Healthcare Holdings Co., Ltd. Corporate Events

Hygeia Healthcare Announces Leadership Changes
Mar 27, 2025

Hygeia Healthcare Holdings Co., Ltd. announced a change in its executive leadership with Ms. Cheng Huanhuan stepping down as Co-chief Executive Officer to focus on her role as an executive Director and secretary to the Board. Mr. Ren Ai has been appointed as the new Co-chief Executive Officer, bringing over 15 years of management experience from multinational corporations. This leadership change is expected to enhance the company’s operational management and strategic focus, particularly in investment, financing, and supply chain management.

Hygeia Healthcare Announces Board Structure and Roles
Mar 27, 2025

Hygeia Healthcare Holdings Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement outlines the leadership structure, which includes both executive and independent non-executive directors, and specifies their roles in various board committees, potentially impacting the company’s governance and strategic direction.

Hygeia Healthcare Reports Revenue Growth Amidst Profit Decline
Mar 27, 2025

Hygeia Healthcare Holdings Co., Ltd. reported a 9.1% increase in revenue to RMB4,446.1 million for the year ending December 31, 2024, despite a 12.6% drop in net profit to RMB598.3 million. The company also repurchased over 11 million shares, with plans to cancel the remaining shares, and opted not to declare a final dividend for the year. The release highlights the use of non-IFRS measures to provide a clearer view of financial performance, although these measures have limitations and are not standardized across companies.

Hygeia Healthcare to Present 2024 Annual Results
Mar 27, 2025

Hygeia Healthcare Holdings Co., Ltd. announced that it will hold a conference call on March 28, 2025, to present its 2024 annual results and business operations. This initiative aims to provide shareholders and potential investors with a comprehensive understanding of the company’s financial performance and operational strategies. The presentation will be accessible online, ensuring equal and timely access to information for all stakeholders.

Hygeia Healthcare to Review Annual Results and Dividend Proposal
Mar 17, 2025

Hygeia Healthcare Holdings Co., Ltd. has announced that its board of directors will convene on March 27, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend, which could impact the company’s financial strategy and stakeholder returns.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.